MedPath

Preterm Infants Fed a Human Milk Fortifier

Not Applicable
Not yet recruiting
Conditions
Growth
Interventions
Other: Control Product
Other: Experimental Product 1
Other: Experimental Product 2
Registration Number
NCT05551975
Lead Sponsor
Abbott Nutrition
Brief Summary

This is a double-blind, randomized, multi-center, controlled, parallel study to evaluate the growth and tolerance of preterm infants fed human milk fortifier (HMF).

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
321
Inclusion Criteria
  • Birth weight between 700 g-1500 g.
  • ≤ 32 weeks and 0 days GA at birth.
  • Participant has been classified as appropriate for GA (AGA).
  • Enteral feeding of human milk must be initiated by 21 days of life (birth date is day of life 0)
  • Mother agrees to provide human milk as the exclusive feeding during the study period; use of donor milk is permitted if fortified with study fortifier and use of mother's own milk (when available) is prioritized.
  • Parent(s) agrees to allow infant to receive both human milk and study HMF.
  • Singleton or twin births only.
  • Infant's parent(s) or a LAR has voluntarily signed and dated an ICF, approved by an IRB/IEC and provided HIPAA (or other applicable privacy regulation) authorization prior to any participation in the study.
Exclusion Criteria
  • Enteral feeding of preterm infant formula or HMF for > 7 days.
  • Expected to be transferred to another facility within 30 days of randomization.
  • Serious congenital abnormalities or underlying disease that may affect growth and development.
  • 5-minute APGAR ≤ 4.
  • Receiving systemic steroids at time of randomization.
  • Receiving probiotics at time of randomization.
  • Grade Ill or IV PVH/IVH.
  • Dependent on invasive ventilation at time of randomization.
  • Maternal incapacity.
  • Mother or infant is currently receiving treatment consistent with HIV therapy.
  • Documentation of maternal use of alcohol or marijuana during pregnancy that in the opinion of the physician is considered abuse.
  • Positive toxicology report for cocaine, opiates, or methamphetamine in mother or infant.
  • Infant has a history of major surgery (intra-thoracic or intra-abdominal procedures or other surgery requiring general anesthesia).
  • Asphyxia defined as progressive hypoxemia and hypercapnia with significant metabolic acidemia characterized by APGAR score <3 at 10 minutes, seizures within the first 12 hours of life, or a cord blood gas < 7.0 and seizures and/or severe tonic abnormalities in the first 12 hours of life.
  • Confirmed NEC (Bell's Stage II or III).
  • Confirmed current sepsis.
  • Infant has any other condition that, in the opinion of the investigator, precludes participation in the study.
  • Participation in another study that has not been approved as a concomitant study by AN.
  • Participant has an allergy or intolerance to any ingredient in study fortifier.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control ProductControl ProductControl Human Milk Fortifier added to human milk feedings
Product 1Experimental Product 1Study Human Milk Fortifier added to human milk feedings
Product 2Experimental Product 2Study Human Milk Fortifier added to human milk feedings
Primary Outcome Measures
NameTimeMethod
WeightStudy Day 1 to Study Day 29 or Hospital Discharge if first

Weight gain per day

Secondary Outcome Measures
NameTimeMethod
WeightStudy Day 1 to Study Day 15

Weight gain per day

Head CircumferenceStudy Day 1 to Study Day 15 and Study Day 29

Head circumference gains per week

Feeding IntoleranceStudy Day 1 to Study Day 29

Percent periods NPO, feedings withheld due to gastrointestinal intolerance

LengthStudy Day 1, 8, 15, 22, 29 and Hospital Discharge

Attained length in cm

Head Circumference (HC)Study Day 1, 8, 15, 22, 29 and Hospital Discharge

Attained HC in cm

Full Enteral FeedsStudy Day 1 to Study Day 29

Days to achieve full enteral feeds

Stool CharacteristicsStudy Day 1 to Study Day 29

Percent bloody, black, watery, or hard stools

Trial Locations

Locations (14)

Tufts Medical Center

🇺🇸

Boston, Massachusetts, United States

North Shore University Hospital

🇺🇸

Manhasset, New York, United States

South Miami Hospital

🇺🇸

Miami, Florida, United States

St. Luke's Baptist Hospital

🇺🇸

San Antonio, Texas, United States

The Woman's Hospital of Texas

🇺🇸

Houston, Texas, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

University of New Mexico Children's Hospital

🇺🇸

Albuquerque, New Mexico, United States

WVU Medicine Children's Hospital

🇺🇸

Morgantown, West Virginia, United States

Connecticut Children's Medical Center

🇺🇸

Hartford, Connecticut, United States

UAMS Medical Center

🇺🇸

Little Rock, Arkansas, United States

Banner - University Medical Center

🇺🇸

Phoenix, Arizona, United States

Children's Mercy Hospital

🇺🇸

Kansas City, Missouri, United States

AdventHealth

🇺🇸

Orlando, Florida, United States

University of South Florida

🇺🇸

Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath